cabecera sugerencias web sanidad web iislafe area del investigador

Paragraph before the tabs


Leading Researcher: Marina Berenguer Haym
NMembers: 12 

Member of CiberEHD since 2006 

Medical research lines

Hepatitis B, C, D and E (clinical, virological and immunological studies): Focus on assessing the effectiveness and risk-benefit of new direct-acting antivirals for the treatment of HCV (and to a lesser extent HBV/HDV) both in immunocompetent and liver transplant patients (pre and posttransplant).

Post-liver transplantation (LT) long-term complications: research to study several post-TH complications such as sexual and renal function, diabetes, cardiovascular disease and de novo tumors. Also, prognostic factors for cellular rejection and operational mechanisms involved in tolerance

Hepatocellular carcinoma (HCC) and LT

Wilson's disease Cirrhotic and Non-cirrhotic portal hypertension CMV infection after LT

Clinical research

During 2015 a total of 34 clinical trials were ongoing and/ or approved. Some are listed below:

  • A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cirrhosis.
  • A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
  • Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis (CIRROXABAN)
  • Multicenter, Randomized Phase 2B Study Evaluating Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Cirrhotic Patients With Associated Hyperammonemia and an Episode of Hepatic Encephalopathy STOP-HE Study
  • Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir With or Without Ribavirin (RBV) in Adult Patients With GT1 or GT4 Chronic HCV Infection and Response to Prior Treatment of Early Stage Hepatocellular Carcinoma (GEODE - I)
  • A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
  • A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection With Advanced Cirrhosis and Child-Pugh (CP)-B Hepatic Insufficiency
  • A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (PEARL-I).
  • Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
  • A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
  • Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

Main projects

Role of the cytomegalovirus-specific Cellular Immune Response in the severity of Hepatitis C virus Recurrence After Liver Transplantation - PI13/01770. PI: VICTORIA AGUILERA SANCHO-TELLO. Funding: Instituto de Salud Carlos III (ISCIII). 2014-2016

Quantification of inflammation, fat, iron and fibrosis by MR imaging biomarkers in liver transplant recipients with hepatic C virus recurrent disease. - PI12/01262. PI: LUIS MATÍ BONMATÍ; Co-Investigator: ÁNGEL RUBÍN SUÁREZ. Funding: ISCIII. 2013-2015

True prevalence of hepatitis C virus (HCV): screening with rapid test in saliva (OraQuick) or with immunoassay from dried blood spots in a Health district. - PI15/02010. PI: Marina Berenguer. Funding: ISCIII. 2015-2018

Use of a non-invasive rapid POC anti-HCV antibody test in oral fluid for HCV screening at population level in the Valencia-La Fe Health Department - GLD1400269. PI: Marina Berenguer. Funding: Gilead Sciences, Inc.

Randomized study of two Ribavirin treatment strategies for Chronic Hepatitis E and severe acute forms - ICI14/00367. PI: Rafael Esteban Mur Co-Investigator: María García-Elíz. Funding: ISCIII. 2015-2017.


Acute cellular rejection versus recurrent hepatitis C after liver transplantation: Clinical and pathological features driving a rational diagnostic approach. de la Pena-Moral, JM; Pons, JA; Tome, S; Gude, F; Miras, M; Bermejo, J; Ramirez, P; Berenguer, M; Varo, E; Forteza, J; Parrilla, P. Hepatology Research. 2015 Apr;45(4):423-31. doi: 10.1111/hepr.12369.

Alterations in carbohydrate metabolism in cirrhotic patients before and after liver transplant. Ramos-Prol A, Hervás-Marín D, Rodríguez-Medina B, Campos-Alborg V, Berenguer M, Moya-Herraiz Á, Merino-Torres J. Diabetes Res Clin Pract. 2015 Nov;110(2):123-8. doi: 10.1016/j.diabres.2015.10.002.

Beyond cure: preventing and managing the complications of end-stage liver disease. Berenguer M, García-Eliz M, Baiguera C, Puoti M. Curr Opin HIV AIDS. 2015 Sep;10(5):355-60. doi: 10.1097/COH.0000000000000184.

Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Robles-Diaz, M; Gonzalez-Jimenez, A; Medina-Caliz, I; Stephens, C; Garcia-Cortes, M; Garcia-Munoz, B; Ortega-Alonso, A; Blanco-Reina, E; Gonzalez-Grande, R; Jimenez-Perez, M; Rendon, P; Navarro, JM; Gines, P; Prieto, M; Garcia-Eliz, M; Bessone, F; Brahm, JR; Parana, R; Lucena, MI; Andrade, RJ Alimentary Pharmacology & Therapeutics. 2015 Jan;41(1):116-25. doi: 10.1111/apt.13023.

Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. Salmeron, J; Vinaixa, C; Berenguer, R; Pascasio, JM; Sanchez Ruano, JJ; Serra, MA; Gila, A; Diago, M; Romero-Gomez, M; Navarro, JM; Testillano, M; Fernandez, C; Espinosa, D; Carmona, I; Pons, JA; Jorquera, F; Rodriguez, FJ; Perez, R; Montero, JL; Granados, R; Fernandez, M; Martin, AB; Munoz de Rueda, P; Quiles, R. World Journal Of Gastroenterology. 2015 Aug 14;21(30):9163-74. doi: 10.3748/wjg.v21.i30.9163.

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. Crespo, J; Diago, M; Cabezas, J; Berenguer, M; Broquetas, T; Serra, MA; Morillas, R; Garcia-Samaniego, J; Calleja, JL; Sanchez, JJ; Lens, S; Soto-Fernandez, S; Sacristan, B; Fernandez, I; Lopez-Nunez, C; Buti, M; Romero-Gomez, M; Saez-Royuela, F; Fernandez, C; Jorquera, F; Sanchez-Antolin, G; Manuel Pascasio, J; Cuadrado, A; Hernandez-Guerra, M. Annals Of Hepatology. 2015 Jul-Aug;14(4):477-86.

HIV Infection Does Not Worsen Prognosis of Liver Transplantation for Hepatocellular Carcinoma. Agüero F, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, Rafecas A, Castells L, Abradelo M, Torre-Cisneros J, González-Diéguez L, Salcedo M, Serrano T, Jiménez-Pérez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, Del Campo S, Bilbao I, Romero C, Moreno A, Rimola A, Miro JM; FIPSE investigators. Hepatology. 2015 Oct 30. doi: 10.1002/hep.28321. [Epub ahead of print]

Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Cerini, F; Martinez Gonzalez, J; Torres, F; Puente, A; Casas, M; Vinaixa, C; Berenguer, M; Ardevol, A; Augustin, S; Llop, E; Senosiain, M; Villanueva, C; de la Pena, J; Banares, R; Genesca, J; Sopena, J; Albillos, A; Bosch, J; Hernandez-Gea, V; Garcia-Pagan, JC. Hepatology. 2015 Aug;62(2):575-83. doi: 10.1002/hep.27783.

Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice. Crespo J, Berenguer M, Pérez F, Fernández I, González O, Bárcena R, Buti M, López J, Calleja JL; LEAD-IN Study Group. Gastroenterol Hepatol. 2015 Nov;38(9):517-24. doi: 10.1016/j.gastrohep.2015.04.002.

Management of HCV in the liver transplant setting. Berenguer, Marina. Clinics and research in hepatology and gastroenterology. 2015 Sep; 39 Suppl 1:S115-9. doi: 10.1016/j.clinre.2015.05.004.

Monosegment ALPPS: A new variant of the techniques for rapid hepatic regeneration. Critical review of the initial results of our series. Montalva Oron, EM; Maupoey Ibanez, J; Banuelos Carrillo, R; Bosca Robledo, A; Orbis Castellanos, JF; Moya Herraiz, A; Ballester Valles, C; Perez Rojas, J; Aparicio Urtasun, J; Lopez-Andujar, R. Cirugia Espanola. 2015 Aug-Sep;93(7):436-43. doi: 10.1016/j.ciresp.2015.02.011.

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Hezode, C; Asselah, T; Reddy, KR; Hassanein, T; Berenguer, M; Fleischer-Stepniewska, K; Marcellin, P; Hall, C; Schnell, G; Pilot-Matias, T; Mobashery, N; Redman, R; Vilchez, RA; Pol, S. Lancet. 2015 Jun 20;385(9986):2502-9. doi: 10.1016/S0140-6736(15)60159-3.

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Forns, X; Poordad, F; Pedrosa, M; Berenguer, M; Wedemeyer, H; Ferenci, P; Shiffman, ML; Fried, MW; Lovell, S; Trinh, R; Lopez-Talavera, JC; Everson, G. Liver International. 2015 Nov;35(11):2358-62. doi: 10.1111/liv.12931.

Outcomes in liver transplantation: Does sex matter? Sarkar, M; Watt, KD; Terrault, N; Berenguer, M. Journal Of Hepatology. 2015 Apr;62(4):946-55. doi: 10.1016/j.jhep.2014.11.023. Review.

Overcoming drug resistance in HSV, CMV, HBV and HCV infection. López-Labrador FX, Berenguer M, Navarro D. Future Microbiol. 2015 Nov;10:1759-66. doi: 10.2217/fmb.15.74.

Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study. Castells, L; Rimola, A; Manzardo, C; Valdivieso, A; Luis Montero, J; Barcena, R; Abradelo, M; Xiol, X; Aguilera, V; Salcedo, M; Rodriguez, M; Bernal, C; Suarez, F; Antela, A; Olivares, S; del Campo, S; Laguno, M; Fernandez, JR; de la Rosa, G; Aguero, F; Perez, I; Gonzalez-Garcia, J; Esteban-Mur, JI; Miro, JM. Journal Of Hepatology. 2015 Jan;62(1):92-100. doi: 10.1016/j.jhep.2014.07.034.

Profiles and clinical management of hepatitis C patients in Spain: disHCovery study. Buti M, Franco A, Carmona I, Sánchez-Ruano JJ, Sansó A, Berenguer M, García-Buey L, Hernández-Guerra M, Morillas RM, Ledesma F, Esteban R;disHCovery Study Group. Rev Esp Quimioter. 2015 Jun;28(3):145-53

Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. Bilbao, I; Salcedo, M; Gomez, MA; Jimenez, C; Castroagudin, J; Fabregat, J; Almohalla, C; Herrero, I; Cuervas-Mons, V; Otero, A; Rubin, A; Miras, M; Rodrigo, J; Serrano, T; Crespo, G; De la Mata, M; Bustamante, J; Gonzalez-Dieguez, ML; Moreno, A; Narvaez, I; Guilera, M. Liver Transplantation. 2015 Aug;21(8):1056-65. doi: 10.1002/lt.24172.

Sofosbuvir Compassionate Use Program for Patients With Severe Recurrent Hepatitis C After Liver Transplantation. Forns, X; Charlton, M; Denning, J; McHutchison, JG; Symonds, WT; Brainard, D; Brandt-Sarif, T; Chang, P; Kivett, V; Castells, L; Prieto, M; Fontana, RJ; Baumert, Thomas F; Coilly, A; Londono, MC; Habersetzer, F. Hepatology. 2015 May;61(5):1485-94. doi: 10.1002/hep.27681.

Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. Di Maira, T; Rubin, A; Puchades, L; Aguilera, V; Vinaixa, C; Garcia, M; De Maria, N; Villa, E; Lopez-Andujar, R; San Juan, F; Montalva, E; Perez, J; Prieto, M; Berenguer, M. Liver Transplantation. 2015, 21(6): 812-822.